- Home
- SOR vs MRVI Comparison
SOR vs MRVI Comparison
Compare SOR & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- MRVI
- Stock Information
- Founded
- SOR 1968
- MRVI 2014
- Country
- SOR United States
- MRVI United States
- Employees
- SOR N/A
- MRVI N/A
- Industry
- SOR Investment Managers
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- MRVI Health Care
- Exchange
- SOR Nasdaq
- MRVI Nasdaq
- Market Cap
- SOR 358.4M
- MRVI 371.8M
- IPO Year
- SOR N/A
- MRVI 2020
- Fundamental
- Price
- SOR $44.00
- MRVI $2.45
- Analyst Decision
- SOR
- MRVI Hold
- Analyst Count
- SOR 0
- MRVI 10
- Target Price
- SOR N/A
- MRVI $5.84
- AVG Volume (30 Days)
- SOR 16.2K
- MRVI 1.5M
- Earning Date
- SOR 01-01-0001
- MRVI 08-11-2025
- Dividend Yield
- SOR 7.24%
- MRVI N/A
- EPS Growth
- SOR N/A
- MRVI N/A
- EPS
- SOR 6.50
- MRVI N/A
- Revenue
- SOR N/A
- MRVI $219,830,000.00
- Revenue This Year
- SOR N/A
- MRVI N/A
- Revenue Next Year
- SOR N/A
- MRVI $10.70
- P/E Ratio
- SOR $6.41
- MRVI N/A
- Revenue Growth
- SOR N/A
- MRVI N/A
- 52 Week Low
- SOR $36.41
- MRVI $1.67
- 52 Week High
- SOR $42.75
- MRVI $9.60
- Technical
- Relative Strength Index (RSI)
- SOR 56.59
- MRVI 50.12
- Support Level
- SOR $43.65
- MRVI $2.35
- Resistance Level
- SOR $44.80
- MRVI $2.71
- Average True Range (ATR)
- SOR 0.72
- MRVI 0.17
- MACD
- SOR -0.01
- MRVI 0.01
- Stochastic Oscillator
- SOR 47.70
- MRVI 57.50
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.